Enterprise record

Definium Therapeutics, Inc. logo

Definium Therapeutics, Inc.

Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is i

Follow
More
Reports & analysis (Directory temporarily unavailable)Alpha EvalSave PDFCompareChallenge a ClaimClaim this record

Alpha ID: alpha:company:985d4ad0-a405-41ec-8ed8-2b8c1c2a17d9Version: public-1As of: unavailable

20 published Claims3 sources

Key Claims

Board and committees

Source-backed public-market identity

Index memberships

Current memberships are attached to a specific security and listing. Announcements, effective dates, and removals remain distinct states; Alpha does not infer membership from company size, exchange, or reputation.

No current membership is published in Alpha's tracked index universe.

This is not evidence that the company is absent from every market index.

As of Sep 29, 2026. Rights-filtered public evidence only; no redistribution or model training is granted.

Only source-backed memberships with an explicit public redistribution basis are returned.

Evidence, history and coverage

Additional published Claims

Published evidence records

3 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. Alpha canonical company public projection

    canonical identity · Source published: Date unavailable · Retrieved: Sep 29, 2026

    Supports 5 claims
    • Legal Name: Definium Therapeutics, Inc. · Claim reviewed: Sep 29, 2026
    • Entity Status: Public listing published · Claim reviewed: Sep 29, 2026
    • Published Fact: US · Claim reviewed: Sep 29, 2026
    • Published Fact: Healthcare · Claim reviewed: Sep 29, 2026
    • Published Fact: Biotechnology · Claim reviewed: Sep 29, 2026

  2. SEC DEF 14A 0001193125-26-182034

    sec def 14a · Source published: Apr 27, 2026 · Retrieved: Sep 6, 2026

    Supports 12 claims
    • Leadership Role: Carol A. Vallone: Chair of the Board · Claim reviewed: Sep 29, 2026
    • Leadership Role: Andreas Krebs: Vice Chair of the Board · Claim reviewed: Sep 29, 2026
    • Leadership Role: David Gryska: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Robert Barrow: Chief Executive Officer and Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Roger Adsett: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Roger Crystal: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Suzanne Bruhn: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Brandi L. Roberts: Chief Financial Officer · Claim reviewed: Sep 29, 2026
    • Leadership Role: Daniel Karlin: Chief Medical Officer · Claim reviewed: Sep 29, 2026
    • Leadership Role: Mark R. Sullivan: Chief Legal Officer and Corporate Secretary · Claim reviewed: Sep 29, 2026
    • Leadership Role: Matthew T. Wiley: Chief Commercial Officer · Claim reviewed: Sep 29, 2026
    • Leadership Role: Robert Barrow: Chief Executive Officer · Claim reviewed: Sep 29, 2026

  3. DEF 14A dftx-20260427.htm

    sec proxy · Source published: Apr 27, 2026 · Retrieved: Sep 2, 2026

    Supports 3 claims
    • Leadership Role: David Gryska North Carolina: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Matthew T. Wiley: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Roger Adsett Pennsylvania: Director · Claim reviewed: Sep 29, 2026